Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLK2 | Q86UE8 | 2/20 | 0.82 |
| ▸ | KDR | P35968 | 7/20 | 0.72 |
| ▸ | PDPK1 | O15530 | 3/20 | 0.72 |
| ▸ | RET | P07949 | 10/20 | 0.71 |
| ▸ | PDGFRB | P09619 | 6/20 | 0.71 |
| ▸ | FLT3 | P36888 | 4/20 | 0.68 |
| ▸ | ALK | Q9UM73 | 4/20 | 0.68 |
| ▸ | FGFR1 | P11362 | 4/20 | 0.65 |
| ▸ | CSF1R | P07333 | 2/20 | 0.65 |
| ▸ | SRC | P12931 | 2/20 | 0.65 |
| ▸ | FLT1 | P17948 | 2/20 | 0.65 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.65 |
| ▸ | FLT4 | P35916 | 2/20 | 0.65 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.65 |
| ▸ | ABL1 | P00519 | 2/20 | 0.65 |
| ▸ | JAK3 | P52333 | 2/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.65 |
| ▸ | NPC1 | O15118 | 1/20 | 0.65 |
| ▸ | GMNN | O75496 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16568378 | 1.00 | TLK2 (0.82) | TLK2KDRPDPK1RETPDGFRB | |
| SCHEMBL5362637 | 0.87 | TLK2 (0.77) | TLK2KDRPDPK1RETPDGFRB | |
| SCHEMBL5367740 | 0.86 | TLK2 (0.75) | TLK2KDRPDPK1RETPDGFRB | |
| SCHEMBL5369648 | 0.85 | TLK2 (0.74) | TLK2KDRPDPK1RETPDGFRB | |
| SCHEMBL5361474 | 0.85 | TLK2 (0.70) | TLK2KDRPDPK1RETPDGFRB | |
| SCHEMBL5478517 | 0.84 | PDPK1 (1.00) | TLK2KDRPDPK1RETPDGFRB | |
| SCHEMBL5203211 | 0.84 | PDPK1 (1.00) | TLK2KDRPDPK1RETPDGFRB | |
| SCHEMBL17480334 | 0.83 | TLK2 (0.68) | TLK2KDRPDPK1RETPDGFRB | |
| SCHEMBL30685927 | 0.82 | TLK2 (0.70) | TLK2KDRPDPK1RETPDGFRB | |
| SCHEMBL5368286 | 0.82 | PAK4 (0.69) | TLK2KDRPDPK1RETPDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9458463-B2 | Method for treatment of diabetes by a small molecule inhibitor for GRK5 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2016-10-04 | — | — | US | claimed |
| US-20170240522-A1 | BENZOTHIOPHENE, BENZYLOXYBENZYLIDENE AND INDOLINE DERIVATIVES USEFUL FOR THE TREATMENT OF TUBERCULOSIS | ÉCOLE POLYTECHNIQUE FÉDÉRALE DE LAUSANNE (EPFL) (CH) | 2017-08-24 | — | — | US | disclosed |
| US-20170240522-A1 | BENZOTHIOPHENE, BENZYLOXYBENZYLIDENE AND INDOLINE DERIVATIVES USEFUL FOR THE TREATMENT OF TUBERCULOSIS | ÉCOLE POLYTECHNIQUE FÉDÉRALE DE LAUSANNE (EPFL) (CH) | 2017-08-24 | — | — | US | disclosed |
| US-9458463-B2 | Method for treatment of diabetes by a small molecule inhibitor for GRK5 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2016-10-04 | — | — | US | disclosed |
| WO-2016041972-A1 | BENZOTHIOPHENE, BENZYLOXYBENZYLIDENE AND INDOLINE DERIVATIVES USEFUL FOR THE TREATMENT OF TUBERCULOSIS | ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL) (CH) | 2016-03-24 | — | — | WO | disclosed |
| US-20150079108-A1 | KINASES AS TARGETS FOR ANTI-DIABETIC THERAPY | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2015-03-19 | — | — | US | disclosed |
| US-7202265-B2 | Indolinone combinatorial libraries and related products and methods for the treatment of disease | SUGEN, INC. (US) | 2007-04-10 | — | — | US | disclosed |
| US-7202265-B2 | Indolinone combinatorial libraries and related products and methods for the treatment of disease | SUGEN, INC. (US) | 2007-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150079108-A1 | KINASES AS TARGETS FOR ANTI-DIABETIC THERAPY | GCKR, GRK4, GRK5 | TLK2 143/4885KDR 1123/4885PDPK1 41/4885 |
| US-20170240522-A1 | BENZOTHIOPHENE, BENZYLOXYBENZYLIDENE AND INDOLINE DERIVATIVES USEFUL FOR THE TREATMENT OF TUBERCULOSIS | INMT, IDO2, IDO1 | TLK2 1108/4885KDR 4818/4885PDPK1 1142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.